Anatomic Inc.

Anatomic provides high-quality human iPSC-derived cells and specialized differentiation technologies to support CMT research and therapeutic development. Through its partnership with the CMTA, Anatomic is developing CMT patient-derived Schwann cell precursors, sensory neurons, and motor neurons that can be used to create more physiologically relevant human models of CMT. These models can help researchers better understand how CMT affects different types of nerve cells, evaluate potential treatments, and accelerate the development of new therapies. By providing researchers with high-quality, patient-derived cell models, Anatomic is helping advance CMT research and bring us closer to more effective treatments for the CMT community.